Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: where X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.

Abstract: The invention relates to medicine and can be used for treating a range of diseases in the treatment of which interferon is used. The agent for inducing endogenous interferon is comprised of the compound 6-(3-methoxycarbonyl phenyl) amino-2,4 (1H, 3H)-pyrimidinedione C12H11N3O4 of general formula: (I). The preparation exhibits greater activity both when injected and when administered orally.

Abstract: The invention relates to fungicides and can be used for treating diseases caused by fungi, and also for preventing damage to various materials and agricultural products by fungi. The fungicide is a 2,4-dioxo-5-(2-hydroxy-3,5-dichlorobenzylidiene)amino-1,3-pyrimidine salt of general formula: (A) or a dimer thereof: (B), where X is selected from the series consisting of: Na+, K+, Li+ and NH4+. An effective preparation having anti-fungal activity with a broad spectrum of action is created.

Abstract: The invention is directed to treatment of delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA and treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.

Abstract: The invention relates to medicine and can be used for treating liver lesions caused by chemical or biological agents. The drug for treating liver lesions caused by chemical or biological agents is embodied as 1-(4-bromophenyl)-6-hydroxy-5-nitroso-1,2,3,4-tetrahydropyrimidine-2.4-dione: (I), or salts thereof having the general formula: (II), where X is selected from Na+, K+, Li+, NH4+, NH2CONH3+ or another pharmacologically acceptable cation. The effectiveness of the preparation in treating liver diseases of different etiologies is increased.

Abstract: A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units/day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

Abstract: The invention is directed to a treatment of diseases that are accompanied by quantitative and/or qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme: said agent being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease in the average molecular weight can be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: A treatment for systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation diseases when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent might be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: The inventions relate to antiseptic agents and the method for producing thereof and can be used as a broad-spectrum disinfectant in medicine, veterinary medicine, agriculture etc. The method for producing of biocidal polyguanidine that comprises condensation polymerization of hexamethylenediamine with guanine salt additionally uses hydrazine hydrate during the condensation polymerization process, at the following ratio of components, mass %: hexamethylenediamine 20-55 guanidine salt 25-65 hydrazine hydrate the rest. Biocidal polyguanidine obtained by means of the above-mentioned method, with the following formula: where n—the number of links A in a single unit of the polymer chain, n=1-3; m—the number of links B in a single unit of the polymer chain, m=2-10; z—the number of single units in the polymer chain, z=4-20; Acid—an acid. The inventions allow obtaining a biocidal polyguanidine with high level of broad-spectrum antimicrobial activity.

Abstract: A treatment for the diseases that are accompanied by quantitative and qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: A treatment for systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation diseases when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent might be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient.

Abstract: A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units/day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

Abstract: The inventions relate to hygiene and cosmetology, in particular to skin care. The inventive method for washing the skin by applying washing or cleaning agents and water is characterized in that it uses water with pH level ranging from 3.0 to 6.0, wherein the water flow rate ranges from 0.1 to 5 ml per 1 cm3 of the skin surface. The inventive composition comprises water, mineral salts and oxygen dissolved in said water, and also one or several types of essential proteinogenic amino acids with isoelectric point ranging from 3.0 to 6.0 pH, and its hardness is equal to or less than 0.5 mg-equivalent unit/dm3. The inventive method and composition make it possible to correct complex unfavourable changes of the skin surface layers by providing it with the required pH values during and after the washing and also by maintaining the normal chemical and bacteriological condition of the face skin.

Abstract: The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg.

Abstract: The invention relates to medicine. The inventive method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and organs, consists in orally injecting a DNA ferment in a quantity of 20 000-500 000 Kunz units in a day per 1 kg of the body mass. The single dose of the inventive medicinal preparation for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and organs comprises 20 000-500 000 Kunz units of the DNAse ferment. The oral administration of the above-mentioned important doses of the preparation only allows the catalytically significant amount of DNAse to be absorbed into the systemic circulation in such a way that the dose-dependent treating effect thereof is exhibited.

Abstract: A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units/day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

Abstract: The present invention relates generally to synthetic pyrimidine derivatives and, more particularly, to the methods of deriving the compounds that are the derivatives of 2,8-dithioxo-1H-pyrano[2,3-d: 6,5-d?]dipyrimidine or its 10-aza-analogue. The compounds disclosed in the present invention are shown to possess antiviral activities against, but not limited to, the Herpes virus, the Chlamydia virus, the Influenza virus and HIV. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Abstract: The inventions relate to hygiene and cosmetology, in particular to skin care. The inventive method for washing the face skin by applying washing or cleaning agents and water is characterized in that it uses water with pH level ranging from 3.0 to 6.0, wherein the water flow rate ranges from 0.1 to 5 ml per 1 cm2 of the skin surface. The inventive composition comprises water, mineral salts and oxygen dissolved in said water. and also one or several types of essential proteinogenic amino acids with isoelectric point ranging from 3.0 to 6.0 pH, with the following ratio of the ingredients, % of weight: mineral salts—from 0.01 to 0.1; essential proteinogenic amino acids—from 0.01 to 1; oxygen dissolved in the water—over 0.001 at a temperature of 22° C.; water—the remainder, wherein the composition has the pH level ranging from 3.0 to 6.0 and its hardness is equal to or less than 0.5 mg—equivalent unit/dm3.

Abstract: It is an object of the present invention to provide a solution for creating an effective method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis) without directly affecting the genetic apparatus of the ageing cells.